Hallucinogen persisting perceptual disorder: a scoping review covering frequency, risk factors, prevention, and treatment
Marcus A. Doyle, Susan Ling, Leanna M.W. Lui, Paul Fragnelli, Kayla M Teopiz, Roger Ho, Joshua D. Di Vincenzo, Joshua D. Rosenblat, Emily S. Gillissie, Danica Nogo, Felicia Ceban, Muhammad Youshay Jawad, Roger S McIntyre
Expert Opinion on Drug Safety April 15, 2022 DOI: 10.1080/14740338.2022.2063273 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Scoping review Peer reviewed |
|---|---|
| Keywords | Hallucinogen Perception |
| Citations | 24 |
| Key findings | Hallucinogen persisting perception disorder appears to be an uncommon yet serious event associated with prior hallucinogen exposure. |
Abstract
INTRODUCTION: Hallucinogen persisting perception disorder (HPPD) affects a subset of persons who use hallucinogens and is defined as the repeated experience of hallucinations and other perceptual disturbances as a result of prior intoxications. As select hallucinogens are under development for the treatment of selectmental disorders, there is a need to better characterize this disorder. AREAS COVERED: A scoping review of the literature on HPPD was completed from inception to July 2021. Topics covered in the review herein include treatments for HPPD, prevalence or incidence data on HPPD among different classes of hallucinogens, risk factors for HPPD, and data pertaining to the pathophysiology of HPPD. EXPERT OPINION: Hallucinogen persisting perception disorder appears to be an uncommon yet serious event associated with prior hallucinogen exposure. The renewed interest in psychedelics as potential treatment options for select mental disorders, especially agents with hallucinogenic potential, provides the impetus to characterize HPPD in its frequency, risk and protective factors, key characteristics, as well as other clinical and treatment-related factors.
Citations in the library
Cited by 19
- The Canadian Network for Mood and Anxiety Treatments (CANMAT) Task Force Report: Serotonergic Psychedelic Treatments for Major Depressive Disorder The Canadian Journal of Psychiatry August 17, 2022
- Reconsidering evidence for psychedelic-induced psychosis: an overview of reviews, a systematic review, and meta-analysis of human studies. Molecular Psychiatry March 1, 2025
- Serotonin 5-HT 2B receptor agonism and valvular heart disease: implications for the development of psilocybin and related agents Expert Opinion on Drug Safety August 15, 2023
- Psychedelics for the Treatment of Psychiatric Disorders: Interpreting and Translating Available Evidence and Guidance for Future Research. American Journal of Psychiatry 2025
- Is the psychedelic experience an essential aspect of the therapeutic effect of serotonergic psychedelics? Conceptual, discovery, development and implementation implications for psilocybin and related agents Expert Opinion on Drug Safety August 28, 2023
and 14 more in the library
Cites 28
- Effects of Psilocybin-Assisted Therapy on Major Depressive Disorder JAMA Psychiatry November 4, 2020
- Human hallucinogen research: guidelines for safety. Journal of Psychopharmacology July 1, 2008
- Psilocybin with psychological support for treatment-resistant depression: six-month follow-up. Psychopharmacology November 8, 2017
- Long-term follow-up of psilocybin-assisted psychotherapy for psychiatric and existential distress in patients with life-threatening cancer Journal of Psychopharmacology January 9, 2020
- ADVERSE REACTIONS TO PSYCHEDELIC DRUGS. A REVIEW OF THE LITERATURE The Journal of Nervous and Mental Disease October 1, 1984
and 23 more in the library